TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06602882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chatbot-delivered screening and brief intervention
Description: 1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chatbot-delivered screening and brief intervention
Description: 1. Screening and personalised advice based on AUDIT-C scores, personal reasons for drinking, and specific barriers: For a score of ≥ 3, the participant will be reminded of the level of risks and dangers of alcohol consumption and the benefits of consumption reduction/cessation and will be assessed for the personal reasons for drinking and specific barriers.~2. Warning of alcohol and alcohol-related harms and reminding of benefits of reduced consumption: The Department of Health's health warning booklet, which has been designed by two of our Co-Is, will be used as the educational content.~3. Realistic and personal goals setting: A specific and measurable goal will be set for the upcoming week. For example, I will reduce to 1 bottle of beer in the upcoming week.~4. Motivational enhancement and practical coping strategies: Tangible advice will be given for coping with situational barriers according to their personal reasons for drinking.
Study: NCT06594809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: Upper extremity PNF exercise is an exercise method that dynamically stabilizes the scapula and affect scapular muscles activity (Witt et al., 2011). Upper extremity PNF patterns consisted of four diagonal patterns (D1 flexion, D2 flexion, D1 extension, and D2 extension) and six key components manual contact, body position, verbal cues pattern of movement, timing of movement and resistance. Patient will be at sitting position with involved side up, head, spine, and scapula in neutral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional neck pain treatment
Description: Cervical muscles stretch + Craniocervical retraction ex + Manual therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional neck pain treatment + Blackburn scapular stabilization exercises
Description: The patients will receive Traditional treatment of neck pain and Scapular stabilization exercises (Blackburn exercises). Blackburn exercises are one of the ways to treat scapular dyskinesia. Perform 2 sets of 20 repetitions of each exercise each session (3 sessions per week) for four weeks (panse et al .,2018). The exercise load will be 60% of the one-repetition maximum (1-RM) during the first week due to their first exposure to the exercises. The evaluation of one-repetition maximum (1-RM) will be every week for all exercises. From the second evaluation, more weight will be added (compare to the previous evaluation) to maintain the overload.
Study: NCT06598527

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Radiation source: 6MV photon linear gas pedal is used. Position immobilization: supine position, hands up, vacuum bag or styrofoam immobilization.~Radiotherapy plan design: 4DCT positioning, radiotherapy plan design at 20% respiratory time-phase CT, isocentric irradiation, IMRT or VMAT design.~Definition of target area:~Gross tumor volume (GTV) includes the primary tumor in the lung, excluding lymph nodes. Internal target volume (ITV); Internal target volume (ITV) is formed by the fusion of 10 respiratory phases of GTV; Planning target volume (PTV) is formed by expanding the ITV by 0.5 cm in all directions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-L1 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: PD-L1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: platinum-based double-agent chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: platinum-based double-agent chemotherapy
Study: NCT06586749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B: nurse-led education
Description: Group B: nurse-led education No educational video, will be shown to this group of patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C: nurse-led education and implementation of teleinterventions
Description: Group C: nurse-led education and implementation of teleinterventions An educational video, made for the purposes of the study only, will be shown to them. This is the difference between the two groups
Study: NCT06600841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy（Adebrelimab）
Description: Adebrelimab plus non-platinum chemotherapy（Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel）and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immunotherapy（Adebrelimab）
Description: anti-PD-L1
Study: NCT06598917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Treatment schedule At 4 to 8 weeks after chemotherapy and radiotherapy ended, maintenance S-1 was administered for up to 12 cycles. A cycle was 3 weeks, with S-1 administrated on days 1 to 14 in each cycle.~The initial dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA \&lt; 1.25 m2; 50 mg twice a day for 1.25 m2⩽ BSA \&lt; 1.5 m2; and 60 mg twice a day for BSA ⩾1.5 m2.~Maintenance chemotherapy with S1 was administered for 12 cycles or terminated earlier if there was disease progression, intolerable toxicity, or at the patient's request.
Study: NCT06596395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine and beetroot juice
Description: Combined effect of beetroot juice and caffeine intake on muscular strength, power and endurance performance

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute caffeine
Description: single effect of caffeine intake on muscular strength, power and endurance performance

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute beetroot juice
Description: single effect of beetroot juice intake on muscular strength, power and endurance performance

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single effect of placebo on muscular strength, power and endurance performance
Study: NCT05593380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parenchymal Intracranial pressure monitor
Description: Treatment based on readings from Parenchymal intracranial pressure monitor.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment based on clinical and imaging observations
Description: Treatment based on clinical and imaging observations.
Study: NCT06588361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Based on Kolcoba Comfort Theory
Description: Training Based on Kolcoba Comfort Theory
Study: NCT06596044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA BIC
Description: VA BIC is a suicide prevention strategy that is designed to meet the needs of Veterans who receive acute psychiatric treatment. VA BIC can be delivered by a trained mental health provider (e.g., mental health nurse, social worker, psychologist, psychiatrist). VA BIC includes two synergistic elements to support the patient after a mental health discharge. The elements include a brief educational session, where the patient receives a one-on-one, one-hour, personalized educational session on suicide prevention. The session incorporates aspects of motivational interviewing. The patient then receives 7 regular follow-up contacts that are conducted by the interventionist. Here the interventionist monitors symptoms, assesses treatment adherence, reviews the safety plan, and assists the patient with engaging in steps to promote their well-being. The sessions incorporate aspects of motivational interviewing. Of note patients in this arm will also receive standard care.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.
Study: NCT06601972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Beautifil II LS (Low-Shrinkage)
Description: The most remarkable feature of this light-cured universal composite for anterior and posterior restorations is its unique shrinkage of 0.85 percent by volume

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite
Description: Nanohybrid resin composites are the most popular, because they improve the distribution of fillers in the matrix by combining nanoparticles with submicron particles to achieve better mechanical, chemical, and optical properties
Study: NCT05370495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-201 Ophthalmic Solution 2.0%
Description: SY-201 Ophthalmic Solution 2.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-201 Ophthalmic Solution 1.0%
Description: SY-201 Ophthalmic Solution 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-201 Ophthalmic Solution 0.5%
Description: SY-201 Ophthalmic Solution 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-201 Ophthalmic Solution Vehicle
Description: SY-201 Ophthalmic Solution Vehicle
Study: NCT06541574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Injection
Description: Methotrexate injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Injection
Description: Methotrexate injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Infusion
Description: Methotrexate Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Infusion
Description: Methotrexate Infusion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham Injection
Study: NCT06417216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Head-cancelled virtual reality
Description: Scene in virtual reality moves with the head while performing visual tasks.
Study: NCT06598644

Intervention type: OTHER
Group type: OTHER
Intervention: Cervical SNAGS (C3-C7) + Conventional PT
Description: Cervical SNAGS at C3-C7 with active movements of lateral flexion and rotation with overpressure at the end range. .Frequency: 10 reps 3 times/week for 3 consecutive weeks Intensity: starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-hot pack for 10 minutes 2-Cervical Stretchings for levator scapulae and sternocleidomastoid 3-cervical isometric exercises, 4. Cervical Range of motion exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM (ergon) + Conventional PT
Description: IASTM, ergon applied at levator scapulae and sternocleidomastoid muscle, with 30 strokes at an angle. After that icing done at the levator scapulae and sternocleidomastoid muscle for 5-10 minutes using cold pack.
Study: NCT04883281

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT) with or without chemotherapy
Description: Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with or without chemotherapy
Description: Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, cetuximab, or carboplatin-paclitaxel
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, cetuximab, or carboplatin-paclitaxel
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Study: NCT06603363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40mg
Description: Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (Coronary CTA)
Description: Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Coronary Computed Tomography Angiography (Coronary CTA)
Description: Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test at baseline, 3-month, and 24-month visits.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: Blood test at baseline, 3-month, and 24-month visits.
Study: NCT06594328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: participants of intervention group will receive text message reminder once a week on their mobile phones to brush and floss properly for the study duration
Study: NCT06599801

Intervention type: PROCEDURE
Intervention: Thoracodorsal artery perforator flap reconstruction surgery
Description: Oral squamous cell carcinoma patients underwent reconstruction with thoracodorsal artery perforator (TDAP) flaps following tumor resection.

Intervention type: PROCEDURE
Intervention: Forearm flaps reconstruction surgery
Description: Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection

Intervention type: PROCEDURE
Intervention: Anterolateral thigh flap reconstruction surgery
Description: Oral squamous cell carcinoma patients received the reconstruction with anterolateral thigh flaps after tumor resection

Intervention type: PROCEDURE
Intervention: Fibula flap reconstruction surgery
Description: Oral squamous cell carcinoma patients received the reconstruction with fibula flaps after tumor resection

Intervention type: PROCEDURE
Intervention: Forearm flap reconstruction surgery
Description: Oral squamous cell carcinoma patients received the reconstruction with forearm flaps after tumor resection
Study: NCT04998331

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06700473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: Before the intervention, when their cervical dilatation is 4-5 cm, EC-1, EC-2 and EC-3 will be applied to pregnant women in all groups. After the initial data collection, the researcher TC will apply reiki for approximately 15-20 minutes to pregnant women in the reiki group with cervical dilatation of 4-5 cm. Immediately after the first intervention, the second EC-2 and EC-3 measurements will be performed. The third EC-2 and EC-3 measurements will be performed when the cervical dilatation is 6-7 cm and then the fourth EC-2 and EC-3 measurements will be performed after 15 minutes of reiki application. The fifth EC-2 and EC-3 measurements will be performed when the cervical dilatation is 8-9 cm, followed by 15 minutes of reiki and the sixth EC-2 and EC-3 measurements. The final data will be collected one hour after delivery of the placenta with a seventh VAS measurement and administration of the EC-4. The EC-4 will also be reassessed by the researchers online at six weeks postpartum
Study: NCT06704230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video googles
Description: Patients undergoing surgery use video googles and a headphone to distract from surgery
Study: NCT06706245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SET-VR (computer)
Description: Low-immersive version of the SET-VR program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-VR (headset)
Description: High-immersive version of the SET-VR program
Study: NCT06706687

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DISBAND protocol
Description: For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DISBAND protocol
Description: For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DISBAND protocol
Description: For each participant blood samples will be collected, processed and studied to analyse microRNA expression, more specifically investigating non-coding RNA (ncRNA). Each participant will undergo a multimodal neuroimaging session, composed of structural MRI, 1H-MRS and PET.
Study: NCT06704178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NuBest Tall Growth Protein Powder
Description: NuBest Tall Growth Protein Powder includes a proprietary blend of vitamins, minerals, and probiotics designed to enhance children's health outcomes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: The placebo powder is designed to mimic the appearance and taste of the NuBest Tall Growth Protein Powder but does not contain the active ingredients.
Study: NCT06704360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immersive VR pathfinding training
Description: Pathfinding training with immersive VR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy
Description: Only receive conventional cognitive training group
Study: NCT06704711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine 300 MG
Description: They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine 300 MG
Description: They will rinse the solution containing a total of 400 mg of caffeine (20 mL, 2% density) in the mouth for 20 seconds and try to continue the exercise against increasing resistance until exhaustion.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The exercise test will be performed on a bicycle ergometer (Ergometer Exercise Bike SANA 500, Germany) (where the pedaling speed is kept constant at 60 rpm, with an initial load of 50 Watts and a load increase of 25 watts per minute, gradually increasing until the participants become exhausted. To be able to determine the degree of difficulty perceived during the test and The Borg Scale will be used to end the test when the athlete reaches the point of exhaustion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will rinse 20 mL of distilled water in their mouth for 20 seconds.
Study: NCT05135000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTP001
Description: LTP001 will be administered orally once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LTP001 will be administered once daily in the morning
Study: NCT04625946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommendations for lifestyle modification.
Description: All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Recommendations for lifestyle modification.
Description: All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.